Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy
Study Details
Study Description
Brief Summary
rhThrombin is a serine protease from human.The study is to assess the Safety, Tolerability, Immunogenicity and efficacy of rhThrombin.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
The study is a randomized, single-blind,blank controlled phase 1&2 trial ,including 3 independent parts toevaluate the safety,efficacy and immunogenicity.
The first part is ascending dose,blank control tolerability and safety study. The Starting doses from 500IU/ml to 1000IU/mL and 2000IU/mL to evaluate the safety,efficacy.
The second part is randomized, single-blind, blank controlled study to evaluate safety、efficacy and immunogenicity. Doses settings :1000IU/mL , 2000IU/mL and blank group which with absorbable collagen sponge when used.
The third part is randomized, single-blind, blank controlled study to evaluate safety、efficacy and immunogenicity. Doses settings :1000IU/mL , 2000IU/mL and blank group which directly sprayed on hemorrhagic point when used.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: rhThrombin ( Topical ) Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy; |
Drug: rhThrombin ( Topical )
Active Substance
Other Names:
|
Placebo Comparator: placebo Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy; |
Drug: placebo
saline solution
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence and Severity of adverse events [baseline to 4 weeks]
Incidence and Severity of adverse events
Secondary Outcome Measures
- Proportion of Subjects Achieving Hemostasis by Six Minutes After Treatment Start [From start of treatment until 6 minutes after treatment start]
Subjects achieving hemostasis at the target bleeding site by 6 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure
- The hemostatic time of the woud [From start of treatment until 6 minutes after treatment start]
The hemostatic time of the woud
- immunogenicity [baseline to 4 weeks]
Incidence of rhThrombin antibody and Confirm whether they are neutralizing antibody
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and female subjects between 18 and 75 years of age;
-
Hepar wedge resection or anatomic hepatectomy(one to five continue hepatic segments) (remark:including open surgery or hand-assisted laparoscopic surgery,patients who has been cholecystectomy or choledochotomy can be also get into the study);
-
Blood routine(including WBC、ANC、RBC、Hb and PLT) and Liver function(ALT≤1.5ULN、AST≤1.5ULN) is appear normal. ALP、LDH、 TBil、Dbil are normal.(Remark: Patients whose Laboratory tests are abnormal but they are no clinical significance can get into the study);
-
Renal function(including Cr、BUN)、coagulation function(including PT、APTT、TT、INR)、 electrolytes(include K、Na、CL、Ca、P、Mg)and electrocardiogram are normal or anormal.Investigator think they make no difference to operation;
-
No other therapeutic surgery was performed in the first 4 weeks before the subject gets into clinical research the study(in addition to diagnostic surgery).
-
Patients have not used blood products in 24hours before surgery.
-
Meet the requirements of the ethics committee.Sign the informed consent form and visited according to the protocol.
Exclusion Criteria:
-
Blood system diseases are known, including coagulopathy or bleeding tendency;
-
Life signs were not stable for more than 24hours;
-
Severe heart、brain and blood vessel diseases in past 6 months,including TIA、Non-disabling cerebral infarction、myocardial infarction、unstable angina or Intracranial hemorrhage;
-
Using the drugs that have an effect on blood coagulation in 7 days before surgey(including but not limited to: aspirin、clopidogrel、ticlopidine、dipyridamole、ginkgo biloba extract、heparin、warfarin、citrates、hemocoagulase、VitK、ethamsylate and Vitc,etc);
-
Complicated with other serious diseases(active infections,uncontrolled diabetes and hyperthyroidism);
-
Be allergic to thrombin(human)、serum(snake) and proteins (hamster);
-
Female subjects are in lactation or serum pregnancy test are positive;
-
Take part in other clinical trail within 4 weeks before geting into the study;
-
Using the Thrombin products and Antithrombin antibodies or Coagulation V factor antibodies are positive before, after using rhthrombin, it may generate an immune response.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Zhiwei Li | Hangzhou | Zhejiang | China | 310000 |
Sponsors and Collaborators
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Investigators
- Principal Investigator: Zhiwei Li, PhD, The First Affiliated Hospital of Medical School of Zhejiang University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZGrhT001